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~]  Reduced treatment time for colistimethate sodium solution 
" " (Colistin CF) aerosolized by eFIow ® rapid, a novel electronic 
nebuliser 
M. Keller, M. Hug, A. Bucholski. PARI GmbH, Aerosol Research Institute, Munich, Germany 
Ahns: This study was undertaken to assess the in-vitro delivery performance of 3 nfl Colistin CF upon 
aerosolization bytwo jet nebulisers in comparison tothe eFlow ® rapid, a new electronic nebttliser 
generating an aerosol via a perforated vibrating membrane. 
Methods: In-vitro nebulisation efficiency of 1 million units colistinlethate sodium dissolved in 3 nfl 
saline (GrOnenthal GmbH, Aachen) was investigated by breath simulation measurements mimicking 
an adult breathing pattern (15breaths/rain, 500nil tidal volume, inh:exh=l/1). Sample solutiolls 
collected from inspiratory and expiratory tilters were assayed by a validated HPLC-method and 
evaporative light scattering detection. Droplet size distributions were measured by laser diffraction 
utilising a Malvern MasterSizer X for calculation of the Respirable Fraction (RF), Mass Median 
Diameter (MMD) and Geometric Standard Deviation (GSD). Total Output Rate (TOR) was assessed 
by gravinletric measurements a  aconstant inspiratory flow of 20 lJmin. 
Results: see the table. 
LC PLUS ® LC STAR ® eFlow ® rapid 
Drug concentpation 1 M I.E./3 ni l  1 M I.E./3 ni l  1 M I.E./3 ni l  
Del ivered Dose [%]* 34.5 2.3 38.2 1.5 36.0 1.8 
Aerosol losses [%]* 16.6 1.5 18.5 1.2 19.8 2.4 
Nebul izat ion t ime [rain] 8.8 2.1 11.3 0.4 3.4 0.27 
Drug Del ivery Rate [mg/nlin] 3.5 0.25 2.7 0.12 7.2 0.34 
Re spit-able Dose [mg < 5[tm] 17.3 1.31 24.3 0.98 17.7 2.4 
RDDR [mg < 5[q~ahnin] 2.2 0.16 2.1 0.10 5.3 0.15 
MMD [[tin] 3.91 0.15 2.97 0.04 3.94 0.26 
GSD 2.1 0.10 2.1 0.03 1.65 0.04 
FPF [% droplets <5[qn] 63.4 2.29 80.8 0.62 68.9 1.74 
TOR [mg/min] 529 16.2 428 11.0 580.0 68.7 
Conclusions: Delivered and respirable doses were comparable for the PARI LC PLUS ® and eFlow ® 
rapid, but slightly higher for the PARI LC STAR ®. However, nebulisation time was 2.5 3.3 fold 
shorter for eFlow ® rapid helping to improve both, compliance and quality of life. 
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[~  Exploratory Phase II study of recombinant canine gastric lipase 
(r-GL, Merispase ®) in association with pancreatic extracts (PE) for 
the treatment of steatorrhea in CF patients inadequately controlled 
with high doses of PE 
D. Hubert 1, I. Durieu 2, J. Moreau 3, H.G. Posselt 4, N. Kapel 5, R Dorfman 6. 
1CRCM, Cochin hospital, Paris'; 2CRCM, CHR Lyon Sud, Pierre Benite; 
3Department of Gastroenterology and nutrition, Rangueil HosTital, Toulouse, 
France; 4 Klinikum JWG-Uniuersit~it, Frank:j~rt, Germany; 5 Seruice de Coprologie, 
GH Pitid-SalpgtiOre, Paris; 6Meristem Therapeutics', Clermont-Ferrand, France 
Merispase ®, a rGL produced in transgenic maize, was evaluated in a multi- 
center, open-label, dose-finding study in adult CF patients with severe pancreatic 
insufficiency. The aims were to determine the most effective dose of  rGL co- 
administered with PE at higher than the recommended dosage (250,000 U.Ph.Eur) 
on the coefficient of fat absorption (CFA) and to assess the safety of  this 
combination. 11 patients completed the study and received successively rGL at 
300mg/d during 2 weeks, then rGL at 150rag in 3), 450rag in 1) or 600rag 
( n 7) during 2 additional weeks, in association with PE (daily dose of Kreon ® 
)300,000 U.Ph.Eur). A significant increase of  CFA was observed at the most 
effective dose of rGL compared to run-in session with PE alone, 84% vs 71% 
(p 0.030). 7 patients howed a positive response with CFA )90% (n 4) and/or 
decrease in fecal lipid content )50% (n 5). The most effective r-GL daily dose was 
150mg (n 1), 300mg (n 5), or 600 mg (n 1). There were no significant changes 
in digestive symptoms at the most effective dose of rGL. In conclusion, Merispase ®
co-administered with high doses of PE for 14 days improved fat malabsorption i
CF patients inadequately controlled with PE at recommended doses, demonstrating 
the benefit of added lipase. The combination was well tolerated and no antibodies 
against rGL were detected after 28 days of treatment. 
[ ] I n - v i t r o  deposition study of a levofloxacin (LEV) solution into a 
novel human nasal cast model by the PARI SINUS TM 
U. Schusctmig, E. Klopfer, M. Luber, T. Selzer, M. Keller. PAR[ Aerosol Research Institute, 
Steinerstn 15c, Munich, Germany 
Ahn: Predict drug deposition i the nasal cavities, focusing on the pre~ and post surgery situation. 
Methods: Nebulization efficiency was investigated using a deposition cast model. Tiffs cast is based 
on anatomical dimensions and is equipped with two cavities (sinuses) in frontal, maxillary and 
sphenoid position. Cavities as well as orifices (ostia) are exchangeable, allowing variation of the 
sinus volume (7.5, 12 and 23 nil) and ostium diameter (1.0 and 3.0trml), respectively. The ostittm/ 
volume configuration f the paranasal cavities of the current in-vitro study was as follows: 
Position Ostiuln diameter × length Sinus volulr~e 
Left Right Left Right 
Frontal 1 × 10 into  3 × 10into 7 .5ml  7 .5ml  
Maxi l lary  1 × 10 irma 3 × 10 irma 23 ln l  23 ln l  
Sphe noid 1 × 10 irma 3 × 10 irma 12 ln l  12 ln l  
Nebulization of 3 tiff LEV solution (5 mg/nfl) was conducted for 4 nfinutes first into the left then 4 
nfinutes into the right nostril of the model. After the experiment the nasal cast model was dismantled 
and drug extracted with solvent from the paranasal cavities including ostia, the nasal cavity, as well as 
from the nebuliser and the filter. LEV content of these solutions was assayed by an internal standard 
HPLC method eveloped inPARI's Pharma laboratories. 
Results: See the graphs. 
Drug Di~tl.ib u~i~n upol~ n~buliza~i~l~ of 15 m~/3ml L~,ofloxaeh~ Singl~ Sinug D~ pm~iti~ n
ml m ml f f l  r~l 
After nebulization, about 3% of the LEV content initially placed into the nebulizer was found in 
all sinus cavities. Deposition i  the single sinus cavities ranged from 24 ~tg (frontal) up to 145 ~tg 
(maxillary). About 70% of the initial drug charge remained in the nebulizer while 6% were found in 
the nasal cavity and 22% were found on the exit tilter. 
Coaelasioas: Large ostium diameters increase deposition when lhaked with a large sinus volume. 
Otherwise deposition decreases with enlarged ostia. 
•]  AAV A264CFTR enhances wt CFTR expression and maturation of 
AF508CFTR 
L. Cebotaru 1 , T.R. Flotte 2, V~ Guggino 1 . 1Johns Hopkins' Uniuersity, Baltimore; 
2Uniuersity ofFlorida, Gainesuille, USA 
We presented previously that delivery of AAV2/5 to the lungs of  Rhesus macaques 
resulted in significant gene transfer. One major limitation to the success of AAV 
gene therapy is that the large size of CFTR fills the packaging capacity of AAV viral 
particles precluding inclusion of a highly efficient promoter. An AAV2/5 vector was 
generated expressing a truncated CFTR insert (A264) driven by a CBA promoter. 
A264CFTR contains the normal coding sequence xcept it is missing the first 264 
amino acids, but was capable of reconstituting physiologic function in vitro and in 
mouse models. 
Aims: To asses the effect of rAAV-CB-A264CFTR vector on CFTR protein 
expression. 
Methods:  Cos7 cells were transfected individually or cotransfected with wt CFTR 
or the AF508 and the rAAV-CB-A264CFTR vector. After 48 hours cells were 
harvested and protein assayed. 
Results: Both wt and A264CFTR could be detected. Wt CFTR was significantly 
increased in cells cotransfected with wtCFTR and rAAV-CB-A264CFTR. An 
increased expression of endogenous wtCFTR was also observed previously when 
monkeys were infected with rAAV-CB-A264CFTR. Both AF508 and A264CFTR 
could also be detected in cotransfected cells. Importantly, in cells cotransfected both 
with AF508 and A264CFTR there was a significant increase in the mature C band 
compared to cells expressing AF508 alone. 
Conclus ion:  rAAV-CB-A264CFTR vector increased expression of Wt CFTR and 
enhanced maturation of AF508 from B to C bands. Several studies have reported 
transcomplementation of AF508 CFTR in cells transfected with only parts of 
CFTR (Cormet-Boyaka, PNAS 101 8221 6, 2004). These fragments improved the 
maturation of AF508 CFTR. Our data suggest hat truncated forms of CFTR may 
be useful gene therapy vectors by affecting the maturation of endogenous CFTR. 
